December 20, 2024
Glaucoma Medications Articles
November 5, 2024
Considering the Time and Money Involved in Prior Authorizations
By Inder Paul Singh, MD
November 1, 2024
Optimizing Drop Size in Ophthalmic Applications
By Constance O. Okeke, MD, MSCE
September 1, 2024
Intraocular Drug Delivery Systems in Glaucoma
By George R. Reiss, MD
September 1, 2024
The Time Is Now
By Nathan M. Radcliffe, MD
June 25, 2024
Trial Data Show Preservative-free Benefit for Glaucoma Treatment
June 1, 2024
Product Spotlight: The First Preservative-free Eye Drop for Glaucoma Debuts
By Karen Appold, contributing writer
June 1, 2024
Real-world Pearls for iDose TR Implantation
By Savak “Sev” Teymoorian, MD, MBA
June 1, 2024
Positive Phase 2b Results for Bimatoprost-eluting Contact Lens
By Conni Koury, contributing editor
June 1, 2024
Landmark Noninferiority Trial Shows Benefit of Microdrops
By Conni Koury, contributing editor
June 1, 2024
FDA Grants SPA for Phase 3 Trial of Dazdotuftide
By Conni Koury, contributing editor
June 1, 2024
Switching to LBN Provided Additional IOP Lowering: Chart Review
By Conni Koury, contributing editor
March 1, 2024
Biodegradable Latanoprost Implant Promising in Phase 2a
By Conni Koury, contributing editor
March 1, 2024
First Patient Treated in Phase 2 Study of Synthetic THC Prodrug for IOP Lowering
By Conni Koury, contributing editor
March 1, 2024
SpyGlass Pharma's Long-term Bimatoprost Implant Studied in Phase 1/2 Trial
By Conni Koury, contributing editor
March 1, 2024
Travoprost Implant Noninferior to Twice-daily Timolol 0.5% Drops
By Conni Koury, contributing editor
March 1, 2024
Travoprost Implant Lowered IOP Better Than Topical PGA Monotherapy
By Conni Koury, contributing editor
March 1, 2024
No Significant ECD Loss Seen With Travoprost Implant
By Conni Koury, contributing editor
March 1, 2024
Surgical Exchange of Travoprost Implant Safe
By Conni Koury, contributing editor
March 1, 2024
At 3 Years IOP Controlled in More Subjects With Travoprost Implant vs Topical Timolol
By Conni Koury, contributing editor
March 1, 2024
Combined Trabecular Microbypass and Goniotomy Effective
By Conni Koury, contributing editor
December 1, 2023
Netarsudil Plus Latanoprost Noninferior to Bimatoprost-timolol Combo
By Conni Koury, contributing editor
September 1, 2023
Emerging Nonsurgical Glaucoma Treatment Options
By TANNER J. FERGUSON, MD, Kristin Mohr, OD
September 1, 2023
FDA Approves Mydcombi Mydriasis Spray on Optejet Platform
By Conni Koury, contributing editor
September 1, 2023
First-in-Class, Dual-MOA Small-molecule Glaucoma Treatment Met Primary Endpoints in Phase 2a Trial
By Conni Koury, contributing editor
September 1, 2023
Omidenepag Isopropyl Drops Effective, May Have Role
By Conni Koury, contributing editor
June 1, 2023
From the Editor: Will Glaucoma Remain Unpredictable Forever?
By Nathan M. Radcliffe, MD
June 1, 2023
Synthetic Cannabinoid Derivative Gets Positive Review for Glaucoma Treatment
By Rochelle Nataloni, contributing writer
June 1, 2023
Celanese to Supply Drug Delivery Platform for Glaukos iDose TR Implant
By Rochelle Nataloni, contributing writer
June 1, 2023
Iyuzeh Shows Similar IOP Lowering to Xalatan in Phase 3 Study
By Rochelle Nataloni, contributing writer
March 1, 2023
Pathology and Management of Neovascular Glaucoma
By Connie M. Wu, MD
March 1, 2023
Treatment of Severe Ocular Surface Disease in the Glaucoma Patient
By Laura Voicu, MD, Sarwat Salim, MD, FACS
March 1, 2023
From the Editor: A Love Letter to Latanoprost
By Nathan M. Radcliffe, MD
March 1, 2023
Glaucoma Myth Busters: Myths About Prostaglandin Analogues and Inflammation
By Khin P. Kilgore, MD, Jason D. Jensen, MD, Sean J. McCafferty, MD
March 1, 2023
FDA Accepts NDA for MydCombi Delivered via Optejet
By Conni Koury, contributing editor
March 1, 2023
Results for iDose TR Exchange Trial Show Good Safety and Tolerability
By Conni Koury, contributing editor
March 1, 2023
Phase 2b Study of MediPrint Proprietary Drug-Eluting Contact Lens for Glaucoma Initiated
By Conni Koury, contributing editor
March 1, 2023
Positive Phase 3 Results for TearClear's Proprietary Preservative-free Latanoprost
By Conni Koury, contributing editor
March 1, 2023
Salvat Laboratories Submits NDA for Clobetasol Nanoemulsion
By Conni Koury, contributing editor
March 1, 2023
Visiox Submits NDA for First Once-daily Brimonidine
By Conni Koury, contributing editor
March 1, 2023
Ocuphire Submits NDA for Nyxol Eye Drops for Mydriasis Reversal
By Conni Koury, contributing editor
December 16, 2022
Thea Pharma Receives FDA Approval for Iyuzeh Preservative-free Latanoprost
By Jennifer Ford, senior managing editor
December 1, 2022
From the Editor: Glaucoma Is a Disease of Change
By Conni Koury, contributing editor
December 1, 2022
FDA Approves Omlonti for IOP Reduction in POAG Patients
By Conni Koury, contributing editor
December 1, 2022
European Medicines Agency Accepts Santen's Application for Preservative-free Latanoprost Emulsion
By Conni Koury, contributing editor
December 1, 2022
SpyGlass Pharma Presents First-in-human Data on IOL-based Drug-delivery Platform
By Conni Koury, contributing editor
December 1, 2022
Daily Sepetaprost Noninferior to Twice-daily Timolol for IOP Lowering
By Conni Koury, contributing editor
September 1, 2022
Exploring Cryopreserved Amniotic Membrane for the Treatment of Glaucoma-related Ocular Surface Disease
By Zarmeena Vendal, MD
September 1, 2022
Patients Are Asking: Can I Take This Medication With a Glaucoma Warning?
By Tirth J. Shah, MD, Lorraine M. Provencher, MD
September 1, 2022
From the Editor: Five Years of Glaucoma Physician
By Nathan M. Radcliffe, MD
September 1, 2022
Black Patients More Likely Than Whites to Have Advanced Vision Loss After Glaucoma Diagnosis
By Conni Koury, contributing editor
September 1, 2022
AAO Commends Congress for Milestone on Prior Authorization Reform
By Conni Koury, contributing editor
September 1, 2022
Drop Instillation Success Linked to Glaucoma Progression
By Conni Koury, contributing editor
September 1, 2022
Netarsudil Significantly Lowered IOP After Trab or Tube Surgery
By Conni Koury, contributing editor
September 1, 2022
Phase 2 Data Favorable for QLS-101 Safety, Efficacy
By Conni Koury, contributing editor
June 1, 2022
Eyenovia Reports Optejet Delivery Technology Reduces Toxicity From Preserved Ophthalmic Solutions
By Conni Koury, contributing editor
June 1, 2022
Glaukos iDose TR Demonstrates IOP Reduction, Favorable Safety in Phase 2b Study
By Conni Koury, contributing editor
June 1, 2022
Thea Completes Acquisition of Akorn's Branded Ophthalmic Products
By Conni Koury, contributing editor
June 1, 2022
Oculis In-licenses Neuroprotective Drug Candidate for Glaucoma
By Conni Koury, contributing editor
June 1, 2022
Survey Reveals Emotional, Social Impact of Hyperemia on Glaucoma Patients
By Conni Koury, contributing editor
March 1, 2022
The Optic Nerve at Night
By Caroline Wilson, MD
March 1, 2022
Factoring Quality of Life Into Glaucoma Treatment
By Deborah Gess Ristvedt, DO
March 1, 2022
COVID-19's Effect on Patient Adherence to Ocular Hypotensive Medication Studied
By Conni Koury, contributing editor
December 1, 2020
Glaucoma Management in the Pregnant Patient
By MARLENE R. MOSTER, M.D., Robert J. Purgert, MD, PhD
December 1, 2020
Bolstering Compliance With Preservative-free Glaucoma Therapies
By JASON BACHARACH, MD
September 1, 2020
From the Editor: Glaucoma Therapy's Fourth Pillar
By Nathan M. Radcliffe, MD
September 1, 2020
Efficacy of SLT as First-Line Therapy
By Jerry Helzner, contributing editor
September 1, 2020
First Eye Success With Xen Predicts Fellow Eye Success
By Jerry Helzner, contributing editor
September 1, 2020
Dogma vs Data: Prostaglandin Use in Glaucoma Patients With Uveitis
By Debra A. Goldstein, MD, Jennifer Lee, MD
June 1, 2020
Improving Patient Compliance With Compounded Glaucoma Medications
By Steven R. Sarkisian, Jr., MD
June 1, 2020
Graybug Studying Sustained-Release Glaucoma Drug
By Jerry Helzner, contributing editor
June 1, 2020
Ocular Therapeutix: Positive Data on Long-Term Implant
By Jerry Helzner, contributing editor
June 1, 2020
Incarcerated Glaucoma Patients Struggle With Adherence
By Jerry Helzner, contributing editor
June 1, 2020
Glaucoma May Be Treatable by Gene Therapy
By Jerry Helzner, contributing editor
June 1, 2020
Patient Satisfaction With Glaucoma Eye Drops
By Jerry Helzner, contributing editor
March 6, 2020
FDA Approves Breakthrough Sustained-Release Glaucoma Implant
By Jerry Helzner, contributing editor
March 4, 2020
Second Phase 3 Trial Validates Efficacy of Bimatoprost SR
By Jerry Helzner, contributing editor
March 1, 2020
The Glaucoma Therapy Pipeline
By John R. Samples, MD
March 1, 2020
Saffron Extract Combats Glaucoma in Preclinical Study
By Jerry Helzner, contributing editor
March 1, 2020
Aerpio Has Good Early Data in Tie2 Regulation
By Jerry Helzner, contributing editor
March 1, 2020
Case Files: A Case of Iridocorneal Endothelial Syndrome
By Matthew Rouse, MD
Advertisement
Recommendations
Advertisement